Physician profile
Thomas Chen
NPI 1457575417
$1,345.90
in general payments reported to CMS, 2019-2025
10 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2021: $375 · 2022: $146 · 2023: $145 · 2024: $69.11 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $393.94 | 2019-2023 | Nxstage System One |
| Apellis Pharmaceuticals, INC. | $137.27 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $133.04 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Travere Therapeutics, INC. | $124.69 | 2023 | |
| Outset Medical INC | $123.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $111.68 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.10 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $69.11 | 2024 | Envarsus |
| Iovance Biotherapeutics, INC. | $43.45 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.